10,539 results match your criteria Acute Promyelocytic Leukemia


Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse.

Proteomics Clin Appl 2019 Jan 16:e1800133. Epub 2019 Jan 16.

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Purpose: Acute promyelocytic leukemia (APL) is the most prognostically favorable subtype of AML. Defining the features that allow identification of acute promyelocytic leukemia (APL) patients likely to relapse after therapy remains challenging.

Experimental Design: Proteomic profiling was performed on 20 newly diagnosed APL, 205 non-APL acute myeloid leukemia (AML), and 10 normal CD34+ samples using Reverse Phase Protein Arrays probed with 230 antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/prca.201800133DOI Listing
January 2019

Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.

Drug Saf 2019 Jan 16. Epub 2019 Jan 16.

Medical Sciences, Indiana University School of Medicine, 1001 E. 3rd St, Bloomington, IN, 47405, USA.

The hedgehog pathway, for which sonic hedgehog (Shh) is the most prominent ligand, is highly conserved and is tightly associated with embryonic development in a number of species. This pathway is also tightly associated with the development of several types of cancer, including basal cell carcinoma (BCC) and acute promyelocytic leukemia, among many others. Inactivating mutations in Patched-1 (PTCH1), leading to ligand-independent pathway activation, are frequent in several cancer types, but most prominent in BCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-018-0777-5DOI Listing
January 2019

Diethyl [(3-phenoxy-2-oxo-4-phenyl-azetidin-1-yl)-phenyl-methyl]-phosphonate as a potent anticancer agent in chemo-differentiation therapy of acute promyelocytic leukemia.

Eur J Pharmacol 2019 Jan 10. Epub 2019 Jan 10.

Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran; Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran, Iran.

Organophosphonates are a group of chemical agents which have high bioactivity. In the present study, we aimed to investigate the anticancer activity of the synthesized β-lactam derivatives of α-amino phosphonates on solid tumor and human leukemic cell lines. The results show that one of these compounds, Diethyl [(3-phenoxy-2-oxo-4-phenyl-azetidine-1-yl)-phenyl-methyl]-phosphonate, is a potent anticancer agent which especially shows anti-leukemic activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2019.01.003DOI Listing
January 2019

Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status.

Int J Biochem Cell Biol 2019 Jan 9;108:7-16. Epub 2019 Jan 9.

Cancer Cell Signaling, Turku Center for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.

Based on the frequent over-expression of c-Myc in hematologic malignancies and its crucial role in the regulation of diverse oncogenic pathways involved in leukomogenesis, intense interest has recently focused on this factor as an appealing therapeutically target in leukemia. In the present study, we aimed to investigate the anti-leukemic property of small molecule inhibitor of c-Myc 10058-F4 in two distinct acute leukemia cell lines consist of acute promyelocytic leukemia (APL)-derived NB4 cells (with wild-type PTEN) and acute lymphoblastic leukemia (ALL)-derived Nalm-6 cells (with down-regulated PTEN). 10058-F4 effectively reduced survival of leukemic cells; however, we found a different cell sensitivity pattern in the tested cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biocel.2019.01.005DOI Listing
January 2019

Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.

Front Med 2019 Jan 12. Epub 2019 Jan 12.

Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Department of Hematology and Oncology, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.

Homoharringtonine (HHT), a plant alkaloid from Cephalotaxus harringtonia, exhibits a unique anticancer mechanism and has been widely used in China to treat patients with acute myeloid leukemia (AML) since the 1970s. Trial SCMC-AML-2009 presented herein was a randomized clinical study designed based on our previous findings that pediatric AML patients younger than two years old may benefit from HHT-containing chemotherapy regimens. Patients randomized to arm A were treated with a standard chemotherapy regimen comprising mainly of anthracyclines and cytarabine (Ara-C), whereas patients in arm B were treated with HHT-containing regimens in which anthracyclines in all but the initial induction therapy were replaced by HHT. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11684-018-0658-4
Publisher Site
http://dx.doi.org/10.1007/s11684-018-0658-4DOI Listing
January 2019
1 Read

RARγ-rearrangements resemble acute promyelocytic leukemia and benefit from 3 + 7 regimen.

Leuk Lymphoma 2019 Jan 11:1-4. Epub 2019 Jan 11.

a Department of Hematology , The First Affiliated Hospital, Zhejiang University College of Medicine , Hangzhou , PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1553302DOI Listing
January 2019
1 Read

[Successful treatment of acute promyelocytic leukemia complicated by liver cirrhosis with all-trans retinoic acid and reduced-dose anthracycline chemotherapy].

Rinsho Ketsueki 2018 ;59(12):2561-2566

Department of Hematology, Toranomon Hospital.

Although all-trans retinoic acids (ATRA) are most commonly used as agents in acute promyelocytic leukemia (APL), there are few reports on the administration of ATRAs to patients with liver insufficiency. We report two cases of APL; a 57-year-old man with APL complicated by liver cirrhosis (Child-Pugh class B) and hepatocellular carcinoma who is receiving transcatheter arterial chemoembolization (TACE) and a 50-year-old man with APL complicated by liver cirrhosis (Child-Pugh class B) who is being prepared for receiving a living-donor liver transplantation. Both patients were successfully treated with a normal dosage of ATRA alone during remission-induction therapy. Read More

View Article

Download full-text PDF

Source
https://www.jstage.jst.go.jp/article/rinketsu/59/12/59_2561/
Publisher Site
http://dx.doi.org/10.11406/rinketsu.59.2561DOI Listing
January 2018
1 Read

An Overview on Arsenic Trioxide-Induced Cardiotoxicity.

Cardiovasc Toxicol 2019 Jan 7. Epub 2019 Jan 7.

Agroprocessing and Natural Products Division, National Institute for Interdisciplinary Science and Technology (CSIR - NIIST), Thiruvananthapuram, Kerala, 695019, India.

Arsenic trioxide (ATO) is among the first-line chemotherapeutic drugs used in oncological practice. It has shown substantial efficacy in treating patients with relapsed or refractory acute promyelocytic leukaemia. The clinical use of ATO is hampered due to cardiotoxicity and hence many patients are precluded from receiving this highly effective treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12012-018-09504-7DOI Listing
January 2019

Droplet digital PCR for quantification of PML-RARα in acute promyelocytic leukemia: a comprehensive comparison with real-time PCR.

Anal Bioanal Chem 2019 Jan 7. Epub 2019 Jan 7.

Department of Laboratory Medicine, Affiliated Hospital of Nantong University, No 20, Xisi Road, Nantong, 226001, Jiangsu, China.

Real-time quantitative PCR (qPCR) has been widely implemented for molecular testing, but there are still some inherent limitations that hamper its usefulness. Droplet digital PCR (ddPCR), which can provide direct, standards-free quantification, has recently received increasing attention. In our study, a comprehensive comparison of ddPCR with qPCR in relation to the quantification of PML-RARα was performed to evaluate the diagnostic potential of ddPCR. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00216-018-1508-6
Publisher Site
http://dx.doi.org/10.1007/s00216-018-1508-6DOI Listing
January 2019
1 Read

[Age-related clinical characteristics and prognosis in non-senile adults with acute myeloid leukemia].

Zhonghua Xue Ye Xue Za Zhi 2018 Dec;39(12):969-976

Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China.

To explore age-related clinical characteristics, early responses and outcomes in non-senile adults with de novo acute myeloid leukemia (AML). Data of consecutive cases of 18-65 years adults with de novo AML (non-acute promyelocytic leukemia) were reviewed retrospectively. Clinical characteristics at diagnosis, early responses and outcomes across different age groups of patients were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.12.001DOI Listing
December 2018

A novel entity of acute myeloid leukaemia with recurrent RARG-rearrangement resembling acute promyelocytic leukaemia.

Leuk Res 2018 Dec 23;77:14-16. Epub 2018 Dec 23.

Department of Hematology& Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183050
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.12.009DOI Listing
December 2018
2 Reads

The effect of simultaneous administration of arsenic trioxide and microvesicles derived from human bone marrow mesenchymal stem cells on cell proliferation and apoptosis of acute myeloid leukemia cell line.

Artif Cells Nanomed Biotechnol 2019 Jan 2:1-9. Epub 2019 Jan 2.

e Department of Medical Biotechnology , Cellular and Molecular Research Centre, Qazvin University of Medical Sciences , Qazvin , Iran.

Acute Promyelocytic Leukemia is one of the most prevalent forms of leukemia which has been treated with arsenic trioxide (ATO) and/or all-trans retinoic acid (ATRA). Although, ATRA and ATO are broadly accessible and administrated, some adverse side effects have been reported recently. Nowadays, microvesicles (MVs) are considered as a potential therapeutic agent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21691401.2018.1489821DOI Listing
January 2019
1 Read

Better treatment outcomes in patients with actively treated therapy-related myeloid neoplasms harboring a normal karyotype.

PLoS One 2018 31;13(12):e0209800. Epub 2018 Dec 31.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.

We analyzed treatment outcomes and prognostic factors in adult patients with therapy-related myeloid neoplasms (t-MNs) to select patients who would be benefited by active anticancer treatment. After excluding 18 patients who received palliative care only and 13 patients with acute promyelocytic leukemia, 72 t-MN patients (45 with acute myeloid leukemia and 27 with myelodysplastic syndrome) were retrospectively evaluated. Among them, 10 (13. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0209800PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312245PMC
December 2018
1 Read

Expression of antiapoptotic proteins livin and survivin in pediatric AML patients, as prognostic markers.

Pediatr Hematol Oncol 2018 Dec 27:1-7. Epub 2018 Dec 27.

a Hematology Research Center , Shiraz University of Medical Sciences , Shiraz , Iran.

Objective: Survivin and livin are highly expressed in various malignancies and their expression levels may be related to unfavorable prognosis. The aim was to investigate the relationships of these two markers with some prognostic factors and with survival of the children with acute myeloid leukemia (AML).

Methods: Livin and survivin expression was investigated quantitatively by immunohistochemistry staining technique in 43 primary formalin-fixed, paraffin-embedded bone marrow blocks in pediatric age group (<18 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08880018.2018.1530702DOI Listing
December 2018
1 Read

Acute Promyelocytic Leukemia: A Summary.

Authors:
Meaghan M Ryan

J Adv Pract Oncol 2018 Mar 1;9(2):178-187. Epub 2018 Mar 1.

Washington University School of Medicine, Saint Louis, Missouri.

Acute promyelocytic leukemia is a distinct subtype of acute myeloid leukemia. The disease is characterized by a chromosomal abnormality involving translocation between chromosomes 15 and 17. Current therapy has advanced to include agents such as all- retinoic acid and arsenic trioxide, which have improved remission and survival rates. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303006PMC
March 2018
9 Reads

[A Case of Suspected Therapy-Related Leukemia after Chemotherapy for Breast Cancer].

Gan To Kagaku Ryoho 2018 Dec;45(12):1775-1777

Dept. of Surgery, Nagato General Hospital.

Therapy-related leukemia(TRL)is a distinctive clinical syndrome that occurs after exposure to chemotherapy or radiotherapy. We report a case of suspected TRLafter chemotherapy in a patient with breast cancer. A 61-year-old woman underwent total mastectomy and sentinel lymph node biopsy(negative)for her breast cancer. Read More

View Article

Download full-text PDF

Source
December 2018
5 Reads

Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.

Diagn Pathol 2018 Dec 22;13(1):98. Epub 2018 Dec 22.

Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, P.zza G. Cesare, 11 70124, Bari, Italy.

Background: Alu repeats, belonging to the Short Interspersed Repetitive Elements (SINEs) class, contain about 25% of CpG sites in the human genome. Alu sequences lie in gene-rich regions, so their methylation is an important transcriptional regulation mechanism. Aberrant Alu methylation has been associated with tumor aggressiveness, and also previously discussed in hematological malignancies, by applying different approaches. Read More

View Article

Download full-text PDF

Source
https://diagnosticpathology.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13000-018-0777-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303857PMC
December 2018
2 Reads

The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.

Leukemia 2018 Dec 21. Epub 2018 Dec 21.

Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Acute promyelocytic leukemia (APL) is characterized by t(15;17)(q22;q21), resulting in a PML-RARA fusion that is the master driver of APL. A few cases that cannot be identified with PML-RARA by using conventional methods (karyotype analysis, FISH, and RT-PCR) involve abnormal promyelocytes that are fully in accordance with APL in morphology, cytochemistry, and immunophenotype. To explore the mechanisms involved in pathogenesis and recurrence of morphologically diagnosed APL, we performed comprehensive variant analysis by next-generation sequencing in 111 pediatric patients morphologically diagnosed as APL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0338-zDOI Listing
December 2018
1 Read

Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.

Leukemia 2018 Dec 20. Epub 2018 Dec 20.

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

The objective of this study was to investigate health-related quality of life (HRQOL), symptom burden, and comorbidity profile in long-term acute promyelocytic leukemia (APL) survivors treated with standard chemotherapy. Overall, 307 long-term APL survivors were invited to participate. HRQOL was assessed with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and compared with that of age and sex-matched controls from the general population. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-018-0325-4
Publisher Site
http://dx.doi.org/10.1038/s41375-018-0325-4DOI Listing
December 2018
2 Reads

Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.

Expert Rev Hematol 2018 Dec 20. Epub 2018 Dec 20.

a Hematology, Department of Cellular Biotechnologies and Hematology , Policlinico Umberto 1, 'Sapienza' University , Rome , Italy.

Introduction: The outcome of acute promyelocytic leukemia (APL) has drastically improved following the identification of the PML-RARA oncogene as a key player in the pathogenesis of APL, and the subsequent introduction of all-trans retinoic acid (ATRA) as a therapeutic agent. Areas covered: Randomized trials have recently demonstrated the efficacy of arsenic trioxide (ATO) in combination with ATRA for the front-line treatment of standard and medium risk APL patients. This chemotherapy-free combination is associated with a decreased cumulative rate of relapse, prolonged overall survival and reduced early death rate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1562332DOI Listing
December 2018

Acute promyelocytic leukaemia presenting as necrotising fasciitis of the perineum (Fournier gangrene).

BMJ Case Rep 2018 12 7;11(1). Epub 2018 Dec 7.

Department of Hematology and Oncology, Boston Medical Center, Boston, Massachusetts, USA.

We present a case of an unusual presentation of acute promyelocytic leukaemia (APML), which presented with Fournier gangrene (FG). A 38-year-old man presented with malaise, groin swelling, anal bleeding, fever and was found to have FG. Initial workup revealed pancytopaenia, borderline low fibrinogen, prolonged international normalized ratio (INR), which raised the suspicion for leukaemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-226837DOI Listing
December 2018
3 Reads

BRD4 interacts with PML/RARα in acute promyelocytic leukemia.

Front Med 2018 Dec 14;12(6):726-734. Epub 2018 Dec 14.

State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Bromodomain-containing 4 (BRD4) has been considered as an important requirement for disease maintenance and an attractive therapeutic target for cancer therapy. This protein can be targeted by JQ1, a selective small-molecule inhibitor. However, few studies have investigated whether BRD4 influenced acute promyelocytic leukemia (APL), and whether BRD4 had interaction with promyelocytic leukemia-retinoic acid receptor α (PML/RARα) fusion protein to some extent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11684-017-0604-xDOI Listing
December 2018
1 Read

The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia.

Onco Targets Ther 2018 22;11:8265-8272. Epub 2018 Nov 22.

Division of Hematology and Oncology, Rhode Island Hospital, The Alpert Medical School of Brown University, Providence, RI, USA,

Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of targeted therapy with accelerated approval in the United States in 2000 gave way to fear over increased toxicity in the absence of efficacy, which subsequently resulted in the drug manufacturer voluntarily withdrawing GO from the market in 2010. We outline the history of GO in terms of initial drug development and early clinical trials that ultimately led the way to GO frontline use in AML based on a series of Phase III studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S150807DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254990PMC
November 2018

PML/RARA inhibits expression of HSP90 and its target AKT.

Br J Haematol 2018 Dec 9. Epub 2018 Dec 9.

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Essential for cell survival, the 90 kD Heat Shock Proteins (HSP90) are molecular chaperons required for conformational stabilization and trafficking of numerous client proteins. Functional HSP90 is required for the stability of AKT, a serine-threonine kinase phosphorylated in response to growth factor stimulation. AKT plays a crucial regulatory role in differentiation, cell cycle, transcription, translation, metabolism and apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15715DOI Listing
December 2018

Pain in patients with newly diagnosed or relapsed acute leukemia.

Support Care Cancer 2018 Dec 8. Epub 2018 Dec 8.

Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, 610 University Ave., 16-712, Toronto, Ontario, M5G 2M9, Canada.

Purpose: Acute leukemia (AL) is associated with substantial morbidity and mortality. We assessed the prevalence and correlates of pain in patients with newly diagnosed or relapsed AL.

Methods: Patients with newly diagnosed or relapsed AL admitted to a comprehensive cancer center completed the Memorial Symptom Assessment Scale (MSAS), which assesses prevalence, severity, and distress associated with pain and other symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-018-4583-5DOI Listing
December 2018

S100A3 a partner protein regulating the stability/activity of RARα and PML-RARα in cellular models of breast/lung cancer and acute myeloid leukemia.

Oncogene 2018 Dec 7. Epub 2018 Dec 7.

Laboratory of Molecular Biology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via La Masa 19, 20156, Milano, Italy.

All trans-retinoic acid (ATRA) is used in the treatment of acute promyelocytic leukemia (APL) and it is a promising agent also in solid tumors. The pharmacological activity of ATRA is mediated by the ligand-activated RAR and RXR transcription factors. In the present study, we define the basal and ATRA dependent RARα interactome in a RARα-overexpressing breast cancer cellular model, identifying 28 nuclear proteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-018-0599-zDOI Listing
December 2018
1 Read

Achieve Automated Organelle Biopsy on Small Single Cells Using a Cell Surgery Robotic System.

IEEE Trans Biomed Eng 2018 Dec 10. Epub 2018 Dec 10.

Single cell surgery such as manipulation or removal of subcellular components or/and organelles from single cells is increasingly used for the study of diseases and their causes in precision medicine. This paper presents a robotic surgery system to achieve automated organelle biopsy of single cells with dimensions of less than 20 μm in diameter. The complexity of spatial detection of the organelle position is reduced by patterning the cells using a microfluidic chip device. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1109/TBME.2018.2885772DOI Listing
December 2018
1 Read

Myelodysplastic syndromes and acute myeloid leukemias in the elderly.

Eur J Intern Med 2018 12;58:28-32

Department of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland. Electronic address:

Most patients above 60 years with acute myeloid leukemia (AML) will die from their disease. Nevertheless, the treatment concepts in elderly patients with myelodysplastic syndromes (MDS) and AML are rapidly evolving. A number of recent reports have identified better survival rates with intensive induction chemotherapy for patients up to 80 years, with the exception of patients with unfavorable genomic risk abnormalities or with major co-morbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejim.2018.05.026DOI Listing
December 2018
1 Read

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.

Leuk Lymphoma 2018 Dec 11:1-10. Epub 2018 Dec 11.

g CIBERONC, Instituto Carlos III , Madrid , Spain.

Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1522438DOI Listing
December 2018

Multiple acute ischemic strokes as the onset manifestation of acute promyelocytic leukemia.

Rom J Intern Med 2018 Dec;56(4):265-268

National Institute of Neurology and Neurovascular Diseases, Bucharest, Romania.

Acute promyelocytic leukemia often manifests with hemorrhagic diathesis, thrombotic events being much rarer. This is the case of a 59-year-old patient with thrombotic cerebro-vascular complications as the onset manifestation of acute promyelocytic leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/rjim-2018-0021DOI Listing
December 2018
2 Reads

Identification of Key Potential Targets and Pathway for Arsenic Trioxide by Systemic Bioinformatics Analysis in Pancreatic Cancer.

Pathol Oncol Res 2018 Nov 30. Epub 2018 Nov 30.

Department of Laboratory Diagnostics, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.

Arsenic trioxide is an approved chemotheraputic agent for the treatment of acute promyelocytic leukemia (APL). Recently, numerous studies suggested that arsenic trioxide acts as anti-cancer roles in various human malignancies. However, the molecular mechanisms are not fully elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-018-0543-0DOI Listing
November 2018
1 Read

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes.

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

GlaxoSmithKline;

Lysine specific demethylase 1 (LSD1) is a histone modifying enzyme that suppresses gene expression through demethylation of lysine 4 on histone H3. The anti-tumor activity of GSK2879552 and GSK-LSD1, potent, selective irreversible inactivators of LSD1, has previously been described.1 Inhibition of LSD1 results in a cytostatic growth inhibitory effect in a range of acute myeloid leukemia cell lines. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.199190DOI Listing
December 2018
5 Reads

Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil - Early Deaths Are Still a Problem.

Clin Lymphoma Myeloma Leuk 2018 Nov 12. Epub 2018 Nov 12.

Institute of Cancer of São Paulo, University of São Paulo, São Paulo, Brazil; Hospital das Clinicas, University of São Paulo, São Paulo, Brazil.

Introduction: Although a considerable improvement in survival of patients with acute promyelocytic leukemia (APL) has been seen over the past decades, real-life outcomes seem to be worse than those reported by prospective studies. We aim to describe clinical characteristics and outcomes of adult patients diagnosed with APL in an academic hospital from the University of Sao Paulo.

Patients And Methods: We retrospectively reviewed the medical charts of 61 patients with APL diagnosed between January 2007 and May 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.11.004DOI Listing
November 2018
1 Read

Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells.

BMC Cancer 2018 Nov 29;18(1):1194. Epub 2018 Nov 29.

Signal Transduction Unit, Section of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 70, 44121, Ferrara, Italy.

Background: The presence of hypoxic areas is common in all breast lesions but no data clearly correlate low oxygenation with the acquisition of malignant features by non-invasive cells, particularly by cells from ductal carcinoma in situ (DCIS), the most frequently diagnosed tumor in women.

Methods: By using a DCIS-derived cell line, we evaluated the effects of low oxygen availability on malignant features of non-invasive breast tumor cells and the possible role of all-trans retinoic acid (ATRA), a well-known anti-leukemic drug, in counteracting the effects of hypoxia. The involvement of the β2 isoform of PI-PLC (PLC-β2), an ATRA target in myeloid leukemia cells, was also investigated by specific modulation of the protein expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-5038-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267073PMC
November 2018
6 Reads

A Survey of Infection in Allogenic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.

Int J Organ Transplant Med 2018 1;9(3):112-116. Epub 2018 Aug 1.

Researcher at Tehran University of Medical Sciences, Tehran, Iran.

Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially cure for acute myeloid leukemia (AML). Patients who undergone HSCT are at increased risk of infection due to impaired immunity.

Objective: To evaluate the rate of bacterial, viral and fungal infection and its relationship with 2-year overall survival of AML patients who had undergone HSCT. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252176PMC
August 2018
8 Reads

Arsenic Trioxide Suppressed Migration and Angiogenesis by Targeting FOXO3a in Gastric Cancer Cells.

Int J Mol Sci 2018 Nov 24;19(12). Epub 2018 Nov 24.

Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing 211166, China.

Arsenic trioxide (As₂O₃), a traditional remedy in Chinese medicine, has been used in acute promyelocytic leukemia (APL) research and clinical treatment. Previous studies have shown that As₂O₃ exerts its potent antitumor effects in solid tumors by regulating cell proliferation and survival. The aim of this study was to investigate whether As₂O₃ inhibited gastric cancer cell migration and angiogenesis by regulating FOXO3a expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms19123739DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321348PMC
November 2018
3 Reads
2.862 Impact Factor

In vitro stability of arsenic trioxide-liposome encapsulates for acute promyelocytic leukemia treatment.

Leuk Res 2019 Jan 16;76:11-14. Epub 2018 Nov 16.

Departamento de Química, Universidade Federal de Santa Maria, 97105-900, Santa Maria, RS, Brazil. Electronic address:

In this work, we investigated the stability of arsenic trioxide (ATO) used in leukemia treatment, encapsulated with nanoliposome, with the aid of ultrasound treatment. Stability studies of As species were followed by liquid chromatography-inductively coupled plasma mass spectrometry (LC-ICP-MS), allowing for the detection of the conversion of low amounts of As(III) to As(V) or the formation of other As species. The influence of storage temperature and time on ATO was evaluated. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183046
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.008DOI Listing
January 2019
7 Reads

The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells.

Haematologica 2018 Nov 22. Epub 2018 Nov 22.

National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy;

CD147 is a transmembrane glycoprotein with multiple functions in human healthy tissues and diseases, in particular in cancer. Overexpression of CD147 correlates with biological functions that promote tumor progression and confers resistance to chemotherapeutic drugs. In contrast to solid tumors, the role of CD147 has not been extensively studied in leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.199661DOI Listing
November 2018
8 Reads

New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.

Cancer Biol Ther 2018 Nov 19:1-5. Epub 2018 Nov 19.

a Department of Gynecology and Obstetrics , Tianjin Medical University General Hospital , Tianjin China.

Acute promyelocytic leukemia (APL) is one of the most fatal hematological malignancies. APL during pregnancy is a rare comorbidity and can lead to adverse outcomes, such as maternal and/or fetal death, without timely and appropriate management. Medical management for APL during pregnancy remains challenging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2018.1529122DOI Listing
November 2018
2 Reads
3.072 Impact Factor

miR-382-5p modulates the ATRA-induced differentiation of acute promyelocytic leukemia by targeting tumor suppressor PTEN.

Cell Signal 2019 Feb 17;54:1-9. Epub 2018 Nov 17.

Central Laboratory of Yong-Chuan Hospital, Chongqing Medical University, Chongqing 402160, China; Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China. Electronic address:

In acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) treatment induces granulocytic differentiation and maturation. MicroRNAs play pivotal roles in formation of the leukemic phenotype. Previously, microRNA-382-5p (miR-382-5p) was upregulated in acute myeloid leukemia (AML) with t(15;17). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08986568183028
Publisher Site
http://dx.doi.org/10.1016/j.cellsig.2018.11.012DOI Listing
February 2019
10 Reads
4.315 Impact Factor

Galectins as potential emerging key targets in different types of leukemia.

Eur J Pharmacol 2019 Feb 16;844:73-78. Epub 2018 Nov 16.

The Department of Hematology and Oncology, The Second Hospital of Jilin University, China. Electronic address:

Galectins are carbohydrate-binding proteins and these have very high affinity for β-galactoside containing glycoproteins and glycolipids. Amongst sixteen types of galectin, the role of galectin 1, 3, 9 and 12 is defined in the development and progression of different types of leukemia including acute myeloid leukemia, acute promyelocytic leukemia, B-cell precursor acute lymphoblastic leukemia, adult T cell leukemia and chronic lymphocytic leukemia. There are multiple mechanisms through which these galectins may affect tumor proliferation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00142999183067
Publisher Site
http://dx.doi.org/10.1016/j.ejphar.2018.11.019DOI Listing
February 2019
11 Reads
2.532 Impact Factor

ACTL6A interacts with p53 in acute promyelocytic leukemia cell lines to affect differentiation via the Sox2/Notch1 signaling pathway.

Cell Signal 2019 Jan 15;53:390-399. Epub 2018 Nov 15.

Central Laboratory of Yong-Chuan Hospital, Chongqing Medical University, Chongqing 402160, China; Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China.

Actin-like 6A (ACTL6A), a component of BAF chromatin remodeling complexes, is important for cell differentiation. Nevertheless, its role and mechanism in acute promyelocytic leukemia (APL) has not been reported. To identify the genes that may participate in the development of APL, we analyzed data from an APL cDNA microarray (GSE12662) in the NCBI database, and found that ACTL6A was up-regulated in APL patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08986568183027
Publisher Site
http://dx.doi.org/10.1016/j.cellsig.2018.11.009DOI Listing
January 2019
9 Reads
4.315 Impact Factor

Novel 1,3,4-thiadiazole-chalcone hybrids containing catechol moiety: synthesis, antioxidant activity, cytotoxicity and DNA interaction studies.

Medchemcomm 2018 Oct 23;9(10):1679-1697. Epub 2018 Aug 23.

Faculty of Science , Department of Chemistry , University of Kragujevac , R. Domanovica 12 , 34000 Kragujevac , Serbia . Email:

Hybrid compounds that combine the 1,3,4-thiadiazole-containing catechol moiety with a chalcone motif were synthesized and examined for their antioxidant activity, cytotoxicity, and DNA-binding activity. A series of thirteen compounds showed strong antioxidant and cytotoxic effects on human acute promyelocytic leukemia HL-60 cells. Several compounds exerted good cytotoxic activities on cervical adenocarcinoma HeLa cells. Read More

View Article

Download full-text PDF

Source
http://xlink.rsc.org/?DOI=C8MD00316E
Publisher Site
http://dx.doi.org/10.1039/c8md00316eDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195102PMC
October 2018
15 Reads

Acute promyelocytic leukaemia with increased basophils.

Br J Haematol 2018 Nov 13. Epub 2018 Nov 13.

Clinical Laboratory of Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.15671
Publisher Site
http://dx.doi.org/10.1111/bjh.15671DOI Listing
November 2018
7 Reads

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pharmacoeconomics 2018 Nov 14. Epub 2018 Nov 14.

Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Center, Maastricht, The Netherlands.

The National Institute for Health and Care Excellence (NICE) invited Teva, the company manufacturing arsenic trioxide (ATO; tradename Trisenox), to submit evidence for the clinical and cost effectiveness of ATO for untreated and relapsed or refractory acute promyelocytic leukaemia (APL). Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Maastricht University Medical Center, was commissioned as the independent Evidence Review Group (ERG). This paper presents a summary of the company submission (CS), the ERG's critical review of the clinical and cost effectiveness evidence in the CS, key methodological considerations and the development of the NICE guidance by the Appraisal Committee (AC). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40273-018-0738-y
Publisher Site
http://dx.doi.org/10.1007/s40273-018-0738-yDOI Listing
November 2018
10 Reads